Rene Kahn
New York, NYNPI 1154861599
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $347,048 of the $357,278 with a category attached, or 97.1%. Alkermes, Inc. accounts for 85.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $105,263 and has fallen 71.2% since, to $30,324 in 2025.
Across 127 payments — averaging $2813.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$305K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- Boehringer Ingelheim International GmbH$12K
- Merck$8K
- Boehringer Ingelheim$6K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $20 from 1 others
What the payments were for
- Consulting fees$347,04897%
- Travel & lodging$7,7652%
- Food & beverage$2,4651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 85 | $304,923 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $20,197 |
| Boehringer Ingelheim International GmbH | 9 | $12,338 |
| Merck | 8 | $7,676 |
| Boehringer Ingelheim | 9 | $6,236 |
| E.r. Squibb & Sons, L.L.C. | 8 | $5,888 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$97,334
- ARISTADA$39,600
- ARISTADA INITIO$9,900
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.